Ascendiant Capital Maintains Buy on Atossa Therapeutics, Lowers Price Target to $24

Benzinga Newsdesk www.benzinga.com Negative 66.2%

Neg 66.2% Neu 0% Pos 0%

Ascendiant Capital analyst Edward Woo maintains Atossa Therapeutics (NASDAQ:ATOS) with a Buy and lowers the price target from $120 to $24.